The association between cataract surgery and atypical antipsychotic use: A nested case-control study

American Journal of Ophthalmology

Volumn 156, Issue 6, 2013, Pages

  Pakzad Vaezi, Kaivon L ^a   Etminan, Mahyar ^a,b   Mikelberg, Frederick S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHLORPROMAZINE; CLOZAPINE; CORTICOSTEROID; HALOPERIDOL; OLANZAPINE; PROCHLORPERAZINE; PROTON PUMP INHIBITOR; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CATARACT; CATARACT EXTRACTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DELUSION; DRUG EFFECT; DRUG USE; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; RISK FACTOR; THOUGHT DISORDER;

EID: 84887998790     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.07.012     Document Type: Article

References (41)

1. D. Pascolini, and S.P. Mariotti Global estimates of visual impairment: 2010 Br J Ophthalmol 96 5 2012 614 618
2. D.B. Rein, P. Zhang, and K.E. Wirth The economic burden of major adult visual disorders in the United States Arch Ophthalmol 124 12 2006 1754 1760
3. P. Mitchell, R.G. Cumming, K. Attebo, and J. Panchapakesan Prevalence of cataract in Australia: the Blue Mountains Eye Study Ophthalmology 104 4 1997 581 588
4. R.G. Cumming, P. Mitchell, and S.R. Leeder Use of inhaled corticosteroids and the risk of cataracts N Engl J Med 337 1 1997 8 14
5. P. Ernst, M. Baltzan, J. Deschênes, and S. Suissa Low-dose inhaled and nasal corticosteroid use and the risk of cataracts Eur Respir J 27 6 2006 1168 1174
6. B.E. Klein, R. Klein, and K.E. Lee Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study Am J Ophthalmol 126 6 1998 782 790
7. N.G. Rowe, P.G. Mitchell, R.G. Cumming, and J.J. Wang Diabetes, fasting blood glucose and age-related cataract: the Blue Mountains Eye Study Ophthalmic Epidemiol 7 2 2000 103 114
8. M. Etminan, F.S. Mikelberg, and J.M. Brophy Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study Ophthalmology 117 6 2010 1251 1255
9. G.M. Richter, M. Torres, F. Choudhury, S.P. Azen, and R. Varma Risk factors for cortical, nuclear, posterior subcapsular, and mixed lens opacities: the Los Angeles Latino Eye Study Ophthalmology 119 3 2012 547 554
10. O.M. Durrani, N.N. Tehrani, J.E. Marr, P. Moradi, P. Stavrou, and P.I. Murray Degree, duration, and causes of visual loss in uveitis Br J Ophthalmol 88 9 2004 1159 1162
11. R.G. Cumming, and P. Mitchell Alcohol, smoking, and cataracts: the Blue Mountains Eye Study Arch Ophthalmol 115 10 1997 1296 1303
12. N.E. Isaac, A.M. Walker, H. Jick, and M. Gorman Exposure to phenothiazine drugs and risk of cataract Arch Ophthalmol 109 2 1991 256 260
13. S. Shahzad, M.I. Suleman, and H. Shahab Cataract occurrence with antipsychotic drugs Psychosomatics 43 5 2002 354 359
14. AstraZeneca Pharmaceuticals Seroquel package insert December 2011 AstraZeneca Pharmaceuticals Wilmington, DE
15. A. Ruigómez, L.A. García Rodríguez, V.J. Dev, F. Arellano, and J. Raniwala Are schizophrenia or antipsychotic drugs a risk factor for cataracts? Epidemiology 11 6 2000 620 623
16. J.A. Lieberman, T.S. Stroup, and J.P. McEvoy Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 12 2005 1209 1223
17. V.B. Souza, F.J. Moura Filho, and F.G. Souza Cataract occurrence in patients treated with antipsychotic drugs Rev Bras Psiquiatr 30 3 2008 222 226
18. F.W. Fraunfelder Twice-yearly exams unnecessary for patients taking quetiapine Am J Ophthalmol 138 5 2004 870 871
19. C.S. Dewa, G. Remington, N. Herrmann, J. Fearnley, and P. Goering How much are atypical antipsychotic agents being used, and do they reach the populations who need them? A Canadian experience Clin Ther 24 9 2002 1466 1476
20. P.S. Wang, S. Schneeweiss, and J. Avorn Risk of death in elderly users of conventional vs. atypical antipsychotic medications N Engl J Med 353 22 2005 2335 2341
21. M. Etminan, F. Forooghian, J.M. Brophy, S.T. Bird, and D. Maberley Oral fluoroquinolones and the risk of retinal detachment JAMA 307 13 2012 1414 1419
22. Population Data British Columbia. Discharge abstract database. Available at: http://www.popdata.bc.ca/data/internal/health/dad. Accessed June 23, 2013.
23. Ministry of Health. Medical Services Plan of British Columbia. Available at http://www.health.gov.bc.ca/msp/index.html. Accessed June 23, 2013.
24. British Columbia Ministry of Health. PharmaNet. Available at: http://www.health.gov.bc.ca/pharmacare/pharmanet/netindex.html. Accessed June 23, 2013.
25. D.H. Solomon, E. Massarotti, R. Garg, J. Liu, C. Canning, and S. Schneeweiss Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis JAMA 305 24 2011 2525 2531
26. K.F. Huybrechts, K.J. Rothman, R.A. Silliman, M.A. Brookhart, and S. Schneeweiss Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes CMAJ 183 7 2011 E411 E419
27. S. Suissa, and L. Azoulay Metformin and the risk of cancer: time-related biases in observational studies Diabetes Care 35 12 2012 2665 2673
28. S.M. Stahl Describing an atypical antipsychotic: receptor binding and its role in pathophysiology Prim Care Companion J Clin Psychiatry 5 suppl 3 2003 9 13
29. S. Vivekanandan, and M.F. Lou Evidence for the presence of phosphoinositide cycle and its involvement in cellular signal transduction in the rabbit lens Curr Eye Res 8 1 1989 101 111
30. R.M. Boerrigter, J.V. Siertsema, and I.P. Kema Serotonin (5-HT) and the rat's eye: some pilot studies Doc Ophthalmol 82 1-2 1992 141 150
31. T.J. Zimmerman, and T.M. Wheeler Miotics: side effects and ways to avoid them Ophthalmology 89 1 1982 76 80
32. E. Uchio, K. Miyakawa, Z. Ikezawa, and S. Ohno Systemic and local immunological features of atopic dermatitis patients with ocular complications Br J Ophthalmol 82 1 1998 82 87
33. X.Y. Zhang, D.F. Zhou, and Y.C. Shen Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia Neuropharmacology 62 5-6 2012 1928 1934
34. J.K. Yao, S. Leonard, and R. Reddy Altered glutathione redox state in schizophrenia Dis Markers 22 1-2 2006 83 93
35. J.K. Yao, R.D. Reddy, and D.P. van Kammen Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications CNS Drugs 15 4 2001 287 310
36. G. Grima, B. Benz, V. Parpura, M. Cuénod, and K.Q. Do Dopamine-induced oxidative stress in neurons with glutathione deficit: implication for schizophrenia Schizophr Res 62 3 2003 213 224
37. W.B. Rathbun, A.J. Schmidt, and A.M. Holleschau Activity loss of glutathione synthesis enzymes associated with human subcapsular cataract Invest Ophthalmol Vis Sci 34 6 1993 2049 2054
38. S.W. Park, C.H. Lee, and J.G. Lee Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells Neurosci Res 69 4 2011 283 290
39. B.M. Al-Chalabi, I.A. Thanoon, and F.A. Ahmed Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients Neuropsychobiology 59 1 2009 8 11
40. G. Dakhale, S. Khanzode, S. Khanzode, A. Saoji, L. Khobragade, and A. Turankar Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics Neuropsychobiology 49 4 2004 205 209
41. T.A. Kato, A. Monji, and Y. Mizoguchi Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? Mini Rev Med Chem 11 7 2011 565 574